Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > To Lou on Yahoo

<< Previous

Bullboard Posts

Next >>

Post by pelabooston Mar 05, 2024 7:59am

226 Views

Post# 35915224

To Lou on Yahoo

Good Morning Lou.

While Merck does likely have some interest in the GOBLET trial, I must point out they are not directly involved in GOBLET. Roche is supplying the CPI Tecentrig aka Atezolizumab for GOBLET.

Merck is involved in the exciting AMBUSH trial.

I do agree that today's news is stellar, and yes, perhaps some dilution. But we took a major step today.

<< Previous

Bullboard Posts

Next >>

BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma-In-Situ: A Patient's Guide